-+ 0.00%
-+ 0.00%
-+ 0.00%

Revolution Medicines presents $198 million in Q3 RASONQUE launch revenue

PUBT·11/04/2026 22:51:28
Listen to the news
Revolution Medicines presents $198 million in Q3 RASONQUE launch revenue
  • Revolution Medicines reported $198 million in third-quarter RASONQUE revenue, reflecting approximately five weeks of commercial availability.
  • More than 5,000 US patients received commercial treatment; functional access exceeded 90% of US pancreatic cancer covered lives.
  • RASONQUE reduced death risk by 60% versus chemotherapy in previously treated metastatic pancreatic cancer; median overall survival reached 13.2 months.
  • European regulators issued a positive CHMP opinion for daraxonrasib; launch preparations are advancing in Japan.
  • Cash and investments totaled $3.7 billion at September 30, 2026; full-year GAAP operating expenses are projected at $2.1 billion–$2.2 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.